<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Fusion Antibodies Plc — News on 6ix</title>
<link>https://6ix.com/company/fusion-antibodies-plc</link>
<description>Latest news and press releases for Fusion Antibodies Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/fusion-antibodies-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e34078dffbe2df127339.webp</url>
<title>Fusion Antibodies Plc</title>
<link>https://6ix.com/company/fusion-antibodies-plc</link>
</image>
<item>
<title>Antibody IP transfer agreement</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/antibody-ip-transfer-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/antibody-ip-transfer-agreement</guid>
<pubDate>Mon, 30 Mar 2026 06:00:00 GMT</pubDate>
<description>Fusion Antibodies plc has entered into an Intellectual Property Transfer Agreement with Finn Therapeutics Ltd, a client, for a novel rabbit antibody, receiving a one-off payment of £250,000. This payment, which will be recognized in the current financial year ending March 31, 2026, is for the IP and related reach through to humanized sequences. The agreement includes tailored payment terms to support the client's fundraising activities, and Finn Therapeutics intends to continue its projects with</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/holdings-in-company-275</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/holdings-in-company-275</guid>
<pubDate>Wed, 04 Feb 2026 15:27:00 GMT</pubDate>
<description>Rathbones Investment Management Ltd, ultimately controlled by Rathbones Group Plc, now holds 9,679,837 ordinary shares in Fusion Antibodies plc, representing approximately 7.74 per cent. of the Company's issued share capital. These shares are registered in the name of Rathbones Nominees Limited.
Disclaimer*</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/total-voting-rights-462</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/total-voting-rights-462</guid>
<pubDate>Fri, 30 Jan 2026 17:00:00 GMT</pubDate>
<description>Fusion Antibodies plc has announced its total voting rights, stating that as of January 30, 2026, the company's issued share capital consists of 125,021,878 ordinary shares of 4 pence each, with each share carrying one voting right. The company holds no shares in treasury, meaning the total number of voting rights available to shareholders is 125,021,878, which will serve as the denominator for FCA Disclosure Guidance and Transparency Rules calculations.
Disclaimer*</description>
</item>
<item>
<title>Issue of Director Shares</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/issue-of-director-shares</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/issue-of-director-shares</guid>
<pubDate>Tue, 27 Jan 2026 07:05:00 GMT</pubDate>
<description>Fusion Antibodies plc has issued 308,720 new ordinary shares at 13 pence per share to executive directors Adrian Kinkaid and Richard Buick, satisfying a portion of their bonuses for the year ended March 31, 2025. This issuance, totaling £40,133.60, is part of a larger fundraising effort announced earlier today. The new shares will be admitted to trading on AIM on January 30, 2026, bringing the total voting rights to 125,021,878.
Disclaimer*</description>
</item>
<item>
<title>Placing and Subscription to raise approx £1.4m</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/placing-and-subscription-to-raise-approx-pound14m</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/placing-and-subscription-to-raise-approx-pound14m</guid>
<pubDate>Tue, 27 Jan 2026 07:00:00 GMT</pubDate>
<description>Fusion Antibodies plc has successfully raised approximately £1.4 million before expenses through a placing and subscription of 11,056,905 new ordinary shares at 13 pence per share. This capital raise, which includes a £19,861.92 subscription by Non-Executive Director Colin Walsh, will be used to accelerate the commercialisation of its OptiMAL® platform, invest in strategic partnerships, fund global marketing efforts, and strengthen proprietary technologies. The company also announced the propose</description>
</item>
<item>
<title>Update on negotiations with NCI regarding OptiMAL</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/update-on-negotiations-with-nci-regarding-optimal</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/update-on-negotiations-with-nci-regarding-optimal</guid>
<pubDate>Fri, 19 Dec 2025 07:00:00 GMT</pubDate>
<description>Fusion Antibodies plc has announced that the National Cancer Institute (NCI) has expressed interest in continuing to use its OptiMAL® platform for antibody discovery, following a successful validation project. Negotiations are underway for an extended collaboration agreement to screen several new targets, with discussions expected to continue into early 2026. While formal approval processes at the US National Institutes of Health are anticipated to take several more months, there is no certainty</description>
</item>
<item>
<title>Launch of OptiMAL platform</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/launch-of-optimal-platform</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/launch-of-optimal-platform</guid>
<pubDate>Tue, 16 Dec 2025 11:04:00 GMT</pubDate>
<description>Fusion Antibodies plc has officially launched its OptiMAL® platform for discovering novel human antibodies, incorporating a proprietary synthetic library and Mammalian Display technology, with the library and its design method protected by US patent no. US12378696 and pending international patents. This launch, presented at the Antibody Engineering and Therapeutics conference, signifies a key development for the company's pre-clinical antibody discovery and engineering services, aiming to accele</description>
</item>
<item>
<title>Mammalian Display video</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/mammalian-display-video</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/mammalian-display-video</guid>
<pubDate>Thu, 11 Dec 2025 07:00:00 GMT</pubDate>
<description>Fusion Antibodies plc is announcing the upcoming commercial launch of its OptiMAL® Human Antibody Discovery platform, featuring a video explaining its Mammalian Display technology, which boasts over 70% transduction efficiency and supports libraries exceeding 10⁹ variants, significantly outperforming competitor platforms. The company will also host a pre-recorded presentation and Q&A session on December 16, 2025, to discuss the launch, with no new material information expected. Investors are enc</description>
</item>
<item>
<title>Half-year Financial Report</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/half-year-financial-report-11</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/half-year-financial-report-11</guid>
<pubDate>Mon, 24 Nov 2025 07:00:00 GMT</pubDate>
<description>Fusion Antibodies plc reported revenues of £0.84 million for the six months ended 30 September 2025, a decrease from £1.2 million in the prior year period, though an increase from the preceding six months. The company saw a significant rise in R&D expenditure to £350,000, contributing to a reduced loss of £0.51 million, a 32% improvement from £0.76 million in H1 FY2025. The cash position stood at £0.25 million as of 30 September 2025, with an additional £543,000 owed by debtors. Key operational </description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/notice-of-results-87</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/notice-of-results-87</guid>
<pubDate>Fri, 21 Nov 2025 07:00:00 GMT</pubDate>
<description>Fusion Antibodies plc will release its unaudited interim results for the six months ended 30 September 2025 on Monday, 24 November 2025, and will host an online investor presentation on Tuesday, 25 November at 11:00 AM GMT to discuss the results and provide a business update.
Disclaimer*</description>
</item>
<item>
<title>OptiMAL Library video</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/optimal-library-video</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/optimal-library-video</guid>
<pubDate>Thu, 13 Nov 2025 07:00:00 GMT</pubDate>
<description>Fusion Antibodies plc has released a video detailing its Opti-library of antibody sequences, a technology protected by US patent no. 17/287,441, which has been integrated into the OptiMAL® library for discovering novel human antibodies. This OptiMAL® library is scheduled for commercial launch in December 2025, and the video is available on the Company's investor hub to provide shareholders with further insight into its technological platforms and service offerings.
Disclaimer*</description>
</item>
<item>
<title>OptiMAL® R&D Update</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/optimalr-randd-update</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/optimalr-randd-update</guid>
<pubDate>Mon, 03 Nov 2025 07:00:00 GMT</pubDate>
<description>Fusion Antibodies plc announced an update on its OptiMAL® R&D project, revealing successful validation for isolating specific antibodies against both proteins and smaller peptide targets. This expands the potential market reach and revenue opportunities for OptiMAL®. The company had previously demonstrated single-digit nM affinities for antibodies against protein targets. The next step involves testing the antibodies in cell-based assays at the National Cancer Institute (NCI) to assess their pot</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/result-of-agm-232</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/result-of-agm-232</guid>
<pubDate>Thu, 16 Oct 2025 12:31:00 GMT</pubDate>
<description>Fusion Antibodies PLC announced that all resolutions were duly passed at the annual general meeting held on October 16, 2025. Full details of the voting results will be available on the Company's website.
Disclaimer*</description>
</item>
<item>
<title>AGM statement and H1 trading update</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/agm-statement-and-h1-trading-update</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/agm-statement-and-h1-trading-update</guid>
<pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
<description>Fusion Antibodies PLC announced unaudited revenues for the first half of the financial year ending March 31, 2026, were approximately £838k, down from £1.2m in the prior year's first half but up from £755k in the second half of last year. The unaudited gross margin for the period was 30%, an increase from 22% in the prior year. Cash as of September 30, 2025, was £251k, tracking in line with management's expectations. The company also highlighted the grant of their US patent covering the OptiMAL®</description>
</item>
<item>
<title>Contract win</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/contract-win-11</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/contract-win-11</guid>
<pubDate>Wed, 08 Oct 2025 06:00:00 GMT</pubDate>
<description>Fusion Antibodies PLC has been selected for a new multi-target Integrated Therapeutic Antibody Services project with a global pharmaceutical company's Antibody Centre of Excellence. The project, under a Master Service Agreement, will focus on humanisation and supply elements, specifically humanising a family of VHH antibody fragments. Fusion will also handle the expression, purification, and supply of research materials. Work on this project is expected to be completed within the current financi</description>
</item>
<item>
<title>Posting of Annual Report & Notice of AGM</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/posting-of-annual-report-and-notice-of-agm-40</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/posting-of-annual-report-and-notice-of-agm-40</guid>
<pubDate>Fri, 19 Sep 2025 11:58:00 GMT</pubDate>
<description>Fusion Antibodies PLC announced that its Annual Report and Accounts for the year ended March 31, 2025, is being posted to shareholders. The Notice of the Company's Annual General Meeting (AGM) is also being distributed. The AGM will occur on Thursday, October 16, 2025, at 11:00 a.m. at the company's Belfast offices. The Notice of AGM and proxy form will be available for download on the company website.
Disclaimer*</description>
</item>
<item>
<title>OptiMAL R&D Update</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/optimal-randd-update</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/optimal-randd-update</guid>
<pubDate>Wed, 17 Sep 2025 06:00:00 GMT</pubDate>
<description>Fusion Antibodies plc announced an update to its OptiMAL R&D project under a collaboration agreement with the National Cancer Institute (NCI). The NCI intends to extend its use of the OptiMAL platform beyond the current agreement ending in November 2025, and negotiations are underway. Fusion Antibodies confirmed that antibodies produced from cells bind to three targets of interest identified by the NCI, with binding affinities within the range expected for commercially viable antibodies, includi</description>
</item>
<item>
<title>Belfast investor presentation</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/belfast-investor-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/belfast-investor-presentation</guid>
<pubDate>Mon, 08 Sep 2025 06:00:00 GMT</pubDate>
<description>Fusion Antibodies PLC will host an in-person investor presentation in Belfast on Thursday, September 18, 2025, following their notification on August 26, 2025. Registered guests are welcomed from 4.15pm, with the presentation scheduled to start at 4.30pm in Belfast City Centre. Those interested in attending can register by sending an email. The company, a specialist in pre-clinical antibody discovery, engineering, and supply, encourages investors to share questions via their investor hub.
</description>
</item>
<item>
<title>Final Results</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/final-results-118</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/final-results-118</guid>
<pubDate>Thu, 04 Sep 2025 06:00:00 GMT</pubDate>
<description>Fusion Antibodies PLC announced its final results for the year ended March 31, 2025, with audited revenues of £1.97 million, a significant increase from £1.14 million in FY2024. The company raised £1.17 million (before expenses) through a placing in March 2025 for working capital and commercial activities. The cash position as of March 31, 2025, was £0.4 million, down from £1.2 million the previous year. The company reported a loss for the financial year of £1.713 million, and a basic loss per s</description>
</item>
<item>
<title>Contract Win</title>
<link>https://6ix.com/company/fusion-antibodies-plc/news/contract-win-12</link>
<guid isPermaLink="true">https://6ix.com/company/fusion-antibodies-plc/news/contract-win-12</guid>
<pubDate>Thu, 28 Aug 2025 06:00:00 GMT</pubDate>
<description>Fusion Antibodies PLC announced on August 28, 2025, that it has been awarded a new humanisation project under an existing Master Service Agreement with a US-based specialty division of a global pharmaceutical company. The company anticipates generating modest revenues from this Humanisation Project, which is expected to be completed within the current financial year. This contract win is strategically important as it demonstrates Fusion's ability to secure contracts with major pharmaceutical com</description>
</item>
</channel>
</rss>